COVID-19: Mithramycin analogs as inhibitors of the complex ACE2- SARS-Cov-2 RBD (receptor-binding domain)
A Spanish company working in pharmaceutical development is the only institution in the world with a library of dozens of mithramycin analogs and the know-how to make further analogs as guided by molecular dynamics to improve the inhibition of the complex ACE2-SARS-Cov-2 RBD (receptor-binding domain). The company is looking for partners for research or technical cooperation agreements.